Physician profile
Debbie Lim
NPI 1477866325
$3,552.41
in general payments reported to CMS, 2019-2025
19 companies · $966 in 2025
The $966 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $258 · 2021: $156 · 2022: $615 · 2023: $723 · 2024: $710 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $41.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.21 |
| Education | $41.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,673.17 | 2019-2025 | |
| Amgen INC. | $686.91 | 2019-2025 | Uplizna, Otezla, Enbrel |
| Janssen Biotech, INC. | $261.55 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $130.91 | 2024-2025 | Taltz |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | Strensiq |
| Novartis Pharmaceuticals Corporation | $124.35 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $114.72 | 2025 | Acthar |
| Glaxosmithkline, LLC. | $65.47 | 2021-2025 | Benlysta |
| Octapharma USA, INC. | $38.14 | 2023-2024 | Panzyga |
| Tg Therapeutics, INC. | $27.91 | 2025 | |
| Ucb, INC. | $26.08 | 2025 | Bimzelx |
| Radius Health, INC. | $25.59 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $24.56 | 2024 | Saphnelo |
| Sandoz INC. | $24.09 | 2024 | Hyrimoz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.30 | 2024 | Actemra |
| Teva Pharmaceuticals USA, INC. | $20.79 | 2023 | Truxima |
| Sobi, INC | $19.25 | 2023 | |
| US Oncology Corporate, INC. | $16.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.